Pfizer Inc. Stock

Weight loss translates to investor profits. Just look at Eli Lilly and Novo Nordisk. Both stocks have skyrocketed thanks largely to their obesity drugs, with Lilly's share price more than

Pfizer (NYSE: PFE) stock is an investing enigma. The drugmaker's shares have printed fresh 52-week lows consistently over the past two years, putting its stock in serious bargain territory. Speaking

Image source: The Motley Fool.

Pfizer (NYSE: PFE)Q1 2024 Earnings CallMay 01, 2024, 10:00 a.m. ET

Operator

Continue reading

Source Fool.com

Pfizer (NYSE: PFE) stock got a very effective shot in the arm on Wednesday. This was supplied by its latest earnings release, which saw the storied pharmaceutical company notch double beats on

Earnings season is officially here. As per usual, there have already been epic sell-offs and run-ups across well-known names.

However, long-term investors know that the best way to view a quarterly

I owned shares of Pfizer (NYSE: PFE) when the COVID-19 pandemic started. Watching the stock soar over 60% in roughly two years was fun. Seeing Pfizer's share price fall nearly 60% from its peak

Income investors can be growth investors, too. Granted, it's not always easy to find stocks that pay generous dividends and offer solid prospects of share price appreciation. However, such stocks

"If you don't find a way to make money while you sleep, you will work until you die." That's a quote from billionaire investor Warren Buffett which emphasizes the importance of making your money

If you had bought $1,000 worth of Pfizer (NYSE: PFE) shares five years ago, how much would that be worth today? The answer will strike you as terrific or terrible: $840.

That answer will be terrible

Pfizer (NYSE: PFE) isn't exactly a hot stock right now. Since its massive run-up during the pandemic's height, built on hopes for its coronavirus vaccine, new sources of growth haven't led to

Income-seeking investors have to make an important choice when shopping for stocks to buy. Shares of companies that are likely to raise their dividend payouts at a rapid pace tend to offer low

Pfizer (NYSE: PFE) stock is relatively cheap. I can easily back up that claim. The big drugmaker's shares trade at lower forward earnings multiples than the S&P 500 and the S&P 500 healthcare

Pfizer (NYSE: PFE) stock has been struggling for a while now. In the past 12 months, it has declined by 36%. A lack of growth recently, a dependence on acquisitions, and many question marks have

Later this year, the Federal Reserve is projected to begin reducing interest rates. While the exact number of rate cuts is still uncertain, this regulatory action is expected to stimulate a surge in

One of the hottest themes in the pharmaceutical industry right now is weight loss. Medications specifically approved for weight loss, such as Wegovy and Zepbound, are taking the industry by storm.

If there were a hedge fund manager hall of fame, Ken Griffin would be a no-brainer inductee. His skillful leadership of Citadel made it one of the most successful hedge funds ever. It also made

Two adages capture the dilemma investors face when they consider buying a beaten-down stock:

These well-known sayings seem to be contradictory. However, they're not when taken in the correct

No pair of companies dominated the COVID-19 vaccine market quite like Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA). Both saw their revenue and earnings skyrocket, along with their share prices, as

A few years ago, both Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) were flying high: from an earnings and share performance perspective. They each sold a leading coronavirus vaccine -- and Pfizer

Few things are more satisfying than watching a steadily growing stream of passive income flow into your brokerage account. If you've been holding back from investing because you think you can't

Cathie Wood and high dividend yields go together like... well, it's hard to finish that sentence because they don't go together at all. Wood and her Ark Invest funds are known for investing in

Does a rising tide really lift all boats? We could soon find out if the adage applies to the stock market.

A bull market is now well underway. The S&P 500 has soared more than 30% over the last 12

Investors looking for stocks that can deliver heaps of passive income might want to turn their heads toward the healthcare sector. Right now, there are a couple of beaten-down stocks offering

Some investors look at Pfizer (NYSE: PFE) as a has-been. That's understandable in some ways. Sales for the company's once-formidable COVID-19 franchise have tanked. So have Pfizer's overall revenue

If a dividend stock is struggling and falling in value, that pushes its yield up. This happens because while you are getting the same dividend, it is now costing you less money to acquire it. As